News | September 10, 2024
Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
The programme is being implemented in collaboration with Grow Well Foundation and is expected to expand in a phased manner
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Subscribe To Our Newsletter & Stay Updated
